Cancer Immunotherapy in Clinical and Translational Research
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".
Deadline for manuscript submissions: 31 December 2024 | Viewed by 124
Special Issue Editor
Interests: clinical and translational research; mechanisms of resistance to anticancer drugs; immunotherapy, non-invasive biomarkers
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Immune checkpoint inhibitors and adoptive cell therapies have significantly improved the survival of patients affected by some of the deadliest tumors. Due to their established anticancer activity, these treatments currently represent one of the main therapeutic options in several oncological settings. Nevertheless, a significant proportion of cancer patients do not respond to immunotherapy. The incorporation of novel biomarkers and the implementation of adapted study designs specific for immunotherapy-based treatments could increase the success rate of this class of agents.
We are pleased to invite you to contribute to this Special Issue focusing on clinical and translational research in cancer immunotherapy.
Original research articles and reviews are welcome. Research areas may include (but are not limited to) preclinical, translational and clinical studies involving multi-omic techniques (such as genomic, transcriptomic, proteomic and immunophenotypic profiling), liquid biopsies and microbiome studies. Articles exploring innovative strategies for adapting clinical trial design for immunotherapy development will also be accepted.
We look forward to receiving your contributions.
Dr. Sofia Genta
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer immunotherapy
- clinical research
- immune checkpoint inhibitor
- cancer vaccines
- biomarker
- translational research
